Logo
x

Search category

Subscribe Now

Gilead

Gilead Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Magrolimab for Acute Myeloid Leukemia

Gilead Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Magrolimab for Acute Myeloid Leukemia

  • August 22, 2023
Gilead Entered into a Multi-Year Collaboration Agreement with Tentarix to Discover and Develop Novel Therapies for Cancer

Gilead Entered into a Multi-Year Collaboration Agreement with Tentarix to Discover and Develop Novel Therapies for Cancer

  • August 16, 2023
Gilead’s Trodelvy (sacituzumab govitecan) Receives EC’s Approval for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead’s Trodelvy (sacituzumab govitecan) Receives EC’s Approval for Pre-Treated HR+/HER2- Metastatic Breast Cancer

  • July 28, 2023
Gilead Receives the US FDA’s Approval of Veklury (remdesivir) sNDA for the Treatment of COVID-19 in Patients with Severe Renal Impairment

Gilead Receives the US FDA’s Approval of Veklury (remdesivir) sNDA for the Treatment of COVID-19 in Patients with Severe Renal Imp...

  • July 14, 2023
Gilead Partnered with Clinton Health Access Initiative and the Pentato to Advance the Development of Dispersible Pediatric Therapies for Children with HIV

Gilead Partnered with Clinton Health Access Initiative and the Pentato to Advance the Development of Dispersible Pediatric Therapi...

  • July 13, 2023
Gilead Presented P-III Trial (MYR301) Results of Hepcludex (bulevirtide) for Chronic Hepatitis Delta Virus at EASL 2023

Gilead Presented P-III Trial (MYR301) Results of Hepcludex (bulevirtide) for Chronic Hepatitis Delta Virus at EASL 2023

  • June 24, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.